ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platformProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-416-8476898
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$475.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/20/2020 (Estimated)
OptionableNot Optionable
Promis Neurosciences (TSE:PMN) Frequently Asked Questions
What is Promis Neurosciences' stock symbol?
Promis Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN."
How were Promis Neurosciences' earnings last quarter?
Promis Neurosciences Inc (TSE:PMN) released its quarterly earnings results on Thursday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.01). View Promis Neurosciences' Earnings History.
When is Promis Neurosciences' next earnings date?
What price target have analysts set for PMN?
1 brokers have issued twelve-month price targets for Promis Neurosciences' stock. Their forecasts range from C$1.00 to C$1.00. On average, they expect Promis Neurosciences' share price to reach C$1.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price. View Analyst Price Targets for Promis Neurosciences.
What is the consensus analysts' recommendation for Promis Neurosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Promis Neurosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Promis Neurosciences.
Has Promis Neurosciences been receiving favorable news coverage?
Media headlines about PMN stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Promis Neurosciences earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Promis Neurosciences.
Who are some of Promis Neurosciences' key competitors?
Some companies that are related to Promis Neurosciences include Emblem (EMC), Enochian Biosciences (ENOB), Matinas BioPharma (MTNB), Monash IVF Group (MVF), Exicure (XCUR), Horizon Discovery Group (HZD), Exicure (XCUR), IMV (IMV), Bioventix (BVXP), Ergomed (ERGO), CorMedix (CRMD), Senesco Technologies (ELOX), Helix Biopharma (HBP), CorMedix (CRMD) and Fennec Pharmaceuticals (FRX).
What other stocks do shareholders of Promis Neurosciences own?
Who are Promis Neurosciences' key executives?
Promis Neurosciences' management team includes the folowing people:
- Mr. Eugene Williams, Exec. Chairman (Age 60)
- Dr. Elliot Goldstein, Pres, CEO & Director (Age 68)
- Dr. Neil R. Cashman, Founder, Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
- Mr. Daniel E. Geffken, Chief Financial Officer (Age 62)
- Dr. Johanne Kaplan, Chief Devel. Officer
How do I buy shares of Promis Neurosciences?
Shares of PMN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Promis Neurosciences' stock price today?
One share of PMN stock can currently be purchased for approximately C$0.21.
How big of a company is Promis Neurosciences?
What is Promis Neurosciences' official website?
How can I contact Promis Neurosciences?
Promis Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The company can be reached via phone at +1-416-8476898.
MarketBeat Community Rating for Promis Neurosciences (TSE PMN)
MarketBeat's community ratings are surveys of what our community members think about Promis Neurosciences and other stocks. Vote "Outperform" if you believe PMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
